GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cline Scientific AB (OSTO:CLINE B) » Definitions » LT-Debt-to-Total-Asset

Cline Scientific AB (OSTO:CLINE B) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Cline Scientific AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cline Scientific AB's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Cline Scientific AB's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).


Cline Scientific AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cline Scientific AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cline Scientific AB LT-Debt-to-Total-Asset Chart

Cline Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only - - - - -

Cline Scientific AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cline Scientific AB LT-Debt-to-Total-Asset Calculation

Cline Scientific AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/22.721
=

Cline Scientific AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/22.721
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cline Scientific AB  (OSTO:CLINE B) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Cline Scientific AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cline Scientific AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cline Scientific AB Business Description

Traded in Other Exchanges
N/A
Address
Vastra Gotalands Lan, 2C Argongatan, Molndal, SWE, 43153
Cline Scientific AB develops and markets products for biomedical research based on proprietary nanotechnology. Its products include unique surfaces for use in stem cell & cancer research and customized nanoparticles for use in biomedical applications.

Cline Scientific AB Headlines

No Headlines